Pet insurance provider Trupanion (NASDAQ: TRUP) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 12.3% year on year to $353.6 million. Its non-GAAP profit of $0.41 per share was 39.1% below analysts’ consensus estimates.

Is now the time to buy TRUP? Find out in our full research report (it’s free).

StockStory’s Take

Trupanion’s second quarter results reflected steady revenue growth, but profitability fell short of Wall Street expectations. Management credited top-line momentum to ongoing strength in the subscription segment, increased pet acquisition spend, and improved operational discipline. CEO Margi Tooth emphasized, “We were able to deploy 16% more into pet acquisition in the quarter as we continue on the pathway to return to prior investment levels, setting up pet growth for the years to come.” Improved retention and a rebound in adjusted operating margins also contributed to the quarter’s overall performance.

Looking to the remainder of 2025, Trupanion’s outlook is focused on balancing disciplined pricing with elevated investment in pet acquisition. Management believes that operational improvements and technology investments will drive efficiency across the business, with Tooth highlighting that “the combination of this improved experience and industry-leading coverage is driving our impressive retention of 98.4% for the quarter.” The company expects a greater contribution from pet growth over price increases, while ongoing moderation in veterinary cost inflation could provide a tailwind for retention and margin stability.

Key Insights from Management’s Remarks

Trupanion’s management pointed to operational discipline, retention gains, and targeted spending as key drivers behind the latest quarter’s performance and future positioning.

• Subscription segment momentum: The subscription business posted 16% year-over-year revenue growth, with management noting robust adjusted operating income and margin expansion as a result of disciplined pricing and higher-value pet acquisitions.
• Retention improvement: Average monthly retention for the trailing three months rose to 98.4%, with Tooth describing this as evidence of the “exceptional and measurable durability” of Trupanion’s offering, even after significant pricing adjustments in the prior year.
• Pet acquisition investment: Spending on pet acquisition increased 16% from last year, which management believes will support future growth as it reaccelerates gross additions and focuses on acquiring higher-lifetime-value pets.
• Veterinary cost trend moderation: Management identified a mild deceleration in veterinary invoice cost inflation, supporting the company’s restored value proposition and allowing for more moderate rate increases moving forward.
• Other business segment slowdown: Revenue growth in the lower-margin other business segment decelerated, as Trupanion is no longer enrolling new pets in most U.S. states for its largest partner. This contributed to a more focused approach on core subscription growth and sustainable margin expansion.

Drivers of Future Performance

Trupanion’s forward guidance is anchored on sustained pet acquisition, improved retention, and moderating veterinary cost trends.

• Greater contribution from pet volume: Management expects a higher share of subscription revenue growth to come from net new pets rather than price increases, as pet acquisition spend continues to rise and channels are focused on higher-lifetime-value additions.
• Technology-driven efficiency: Long-term investments in automation and direct payment software are expected to enhance invoice processing, member experience, and operational leverage, supporting margin stability.
• Veterinary cost inflation risk: While a deceleration in veterinary invoice costs has emerged, any renewed cost pressure could impact future pricing actions and retention, as management remains cautious about industry-wide input costs.

Catalysts in Upcoming Quarters

Our analyst team will be closely monitoring (1) the pace of net new pet additions as pet acquisition spending rises, (2) trends in veterinary cost inflation and their impact on pricing strategies, and (3) continued improvement in member retention as prior rate increases cycle through. Progress in launching adjacent products, especially the food initiative, may also serve as a future growth lever.

Trupanion currently trades at $50.30, up from $48.81 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.

Don’t let fear keep you from great opportunities and take a look at Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.